The Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal and IRICoR Announce initiation of Phase 1 Trial of Licensed Small Molecule Therapy for Solid Tumors Français
MONTRÉAL , July 8, 2025 /CNW/ - IRIC and IRICoR today announced the start of a Phase 1 clinical trial of its small molecule therapy for solid tumors licensed to Ipsen. This marks a major milestone in the strategic collaboration between the partners, which began in May 2020 with a research and option agreement followed by a licensing agreement in February 2023.
The small molecule clinical candidate, now known as IPN01195, is a RAF inhibitor, an important target in a signaling pathway involved in cancer cell growth and proliferation. It was originally discovered and developed by the teams of Professors Marc Therrien and Anne Marinier at the Université de Montréal's Institute for Research in Immunology and Cancer (IRIC) and has shown promising activity in preclinical models of various solid tumors.
"We are extremely proud to see our novel small molecule therapy reaching this important clinical milestone. This is another example of the efficiency and innovative approach of IRIC's collaborative drug discovery research model," said Dr. Anne Marinier, Director of the Drug Discovery Unit at IRIC. "This marks a major step forward for our multidisciplinary teams of biologists and chemists, but more importantly, it brings us closer to delivering a potential new treatment option for patients facing advanced cancers," said Dr. Marc Therrien, Principal Investigator, Intracellular Signalling Research Unit and Chief Executive Officer, IRIC. "We are delighted by the commitment and progress of our partner Ipsen, and we look forward to the continued development of this promising therapy," concluded Dr. Marinier.
"The initiation of this clinical trial marks a major validation of our business development efforts," said Elizabeth Douville, CEO, IRICoR. "It demonstrates our ability to translate novel science into programs that attract world-class partners and progress into the clinic. With additional first-in-class and best-in-class molecules targeting key cancer pathways in our pipeline, we are actively exploring new strategic collaborations and raising capital to accelerate development. This is an exciting inflection point for IRICoR as we continue to deliver both scientific and commercial value," added Elizabeth Douville.
Under the terms of the agreement, the Université de Montréal granted Ipsen exclusive rights to develop and commercialize the compound globally. The University and IRICoR are eligible to receive development and commercial milestone payments, as well as royalties on net sales.
About the Institute for Research in Immunology and Cancer of the Université de Montréal
An ultra-modern research hub and training centre located in the heart of the Université de Montréal, the Institute for Research in Immunology and Cancer of the Université de Montréal was created in 2003 to shed light on the mechanisms of cancer and discover new, more effective therapies to counter this disease. The IRIC operates according to a model that is unique in Canada. Its innovative approach to research has already led to discoveries that will, over the coming years, have a significant impact on the fight against cancer. For more information about IRIC, visit www.iric.ca/en.
Founded in 2008 by Université de Montréal's Institute for Research in Immunology and Cancer, IRICoR's mission is to accelerate the discovery, development and commercialization of innovative therapies in oncology, immunotherapy and rare diseases. IRICoR plays an essential role in establishing strategic partnerships with the biopharmaceutical industry or creating spin-off companies, thus facilitating the transformation of academic research projects into new therapies for the benefit of patients. Thanks to its crucial financial support, IRICoR enables researchers to bridge the gap between academic research and the business world. For more information about IRICoR, visit www.iricor.ca/en/.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
08-07-2025
- Cision Canada
The Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal and IRICoR Announce initiation of Phase 1 Trial of Licensed Small Molecule Therapy for Solid Tumors Français
Milestone marks a key advancement in the partnership with Ipsen. MONTRÉAL , July 8, 2025 /CNW/ - IRIC and IRICoR today announced the start of a Phase 1 clinical trial of its small molecule therapy for solid tumors licensed to Ipsen. This marks a major milestone in the strategic collaboration between the partners, which began in May 2020 with a research and option agreement followed by a licensing agreement in February 2023. The small molecule clinical candidate, now known as IPN01195, is a RAF inhibitor, an important target in a signaling pathway involved in cancer cell growth and proliferation. It was originally discovered and developed by the teams of Professors Marc Therrien and Anne Marinier at the Université de Montréal's Institute for Research in Immunology and Cancer (IRIC) and has shown promising activity in preclinical models of various solid tumors. "We are extremely proud to see our novel small molecule therapy reaching this important clinical milestone. This is another example of the efficiency and innovative approach of IRIC's collaborative drug discovery research model," said Dr. Anne Marinier, Director of the Drug Discovery Unit at IRIC. "This marks a major step forward for our multidisciplinary teams of biologists and chemists, but more importantly, it brings us closer to delivering a potential new treatment option for patients facing advanced cancers," said Dr. Marc Therrien, Principal Investigator, Intracellular Signalling Research Unit and Chief Executive Officer, IRIC. "We are delighted by the commitment and progress of our partner Ipsen, and we look forward to the continued development of this promising therapy," concluded Dr. Marinier. "The initiation of this clinical trial marks a major validation of our business development efforts," said Elizabeth Douville, CEO, IRICoR. "It demonstrates our ability to translate novel science into programs that attract world-class partners and progress into the clinic. With additional first-in-class and best-in-class molecules targeting key cancer pathways in our pipeline, we are actively exploring new strategic collaborations and raising capital to accelerate development. This is an exciting inflection point for IRICoR as we continue to deliver both scientific and commercial value," added Elizabeth Douville. Under the terms of the agreement, the Université de Montréal granted Ipsen exclusive rights to develop and commercialize the compound globally. The University and IRICoR are eligible to receive development and commercial milestone payments, as well as royalties on net sales. About the Institute for Research in Immunology and Cancer of the Université de Montréal An ultra-modern research hub and training centre located in the heart of the Université de Montréal, the Institute for Research in Immunology and Cancer of the Université de Montréal was created in 2003 to shed light on the mechanisms of cancer and discover new, more effective therapies to counter this disease. The IRIC operates according to a model that is unique in Canada. Its innovative approach to research has already led to discoveries that will, over the coming years, have a significant impact on the fight against cancer. For more information about IRIC, visit Founded in 2008 by Université de Montréal's Institute for Research in Immunology and Cancer, IRICoR's mission is to accelerate the discovery, development and commercialization of innovative therapies in oncology, immunotherapy and rare diseases. IRICoR plays an essential role in establishing strategic partnerships with the biopharmaceutical industry or creating spin-off companies, thus facilitating the transformation of academic research projects into new therapies for the benefit of patients. Thanks to its crucial financial support, IRICoR enables researchers to bridge the gap between academic research and the business world. For more information about IRICoR, visit
CTV News
26-06-2025
- CTV News
Early childhood study brings active play into Montreal daycares
A Montreal daycare is trying a pilot project called 'active play' that experts say is helping with brain development. A new pilot project in Montreal is using something simple — movement — to help preschoolers build lifelong skills before they even step foot in a classroom. At the Pré-maternelle de la petite italie in the Little Italy neighbourhood, children are running, jumping, stretching, and laughing as part of a project that researchers hope will strengthen both body and brain during the most critical stage of development. 'About 90 per cent of brain development happens before age six,' said Sylvana Côté, a professor at Université de Montréal's School of Public Health and a researcher at the CHU Sainte-Justine. 'When children start school, they should already have acquired several basic skills in order to really benefit from everything school has to offer.' Sylvana Côté Professor Sylvana Côté says that about 90 per cent of brain development happens before age six. (CTV News) Côté is leading the research project, which aims to help young children develop motor, cognitive, and social skills through structured active play. Educators are supported over 14 weeks to integrate movement into daily routines, even in spaces that may lack ideal infrastructure. 'Our goal is to give educators simple, effective tools,' said Côté. 'We offer a portfolio of active games that can be done anywhere, in any weather — even if the daycare doesn't have a backyard or is far from a park.' The project is currently running its pilot in two Montreal daycares, with a planned expansion to 60 centres involving about 2,000 children over the next two years. The goal is to measure not just how much children move, but how their abilities and attitudes toward physical activity change over time. Active children The children at two Montreal daycares are engaged in active play, which is said to develop the brain as well as the body. (CTV News) The long-term aims include improving kids' coordination, balance, and posture, but the broader ambition is to build confidence, enjoyment of movement, and a foundation for lifelong health. 'We do what we like to do, it's a cycle,' said Côté. 'Learning to enjoy movement because we know how to do these movements, that's one of the greatest pleasures in life.' She said these skills shouldn't be taken for granted. 'A little practice and support can make a big difference in how much children enjoy physical activity.' At the Little Italy daycare, educator Marilyn Harper said the impact on children was almost immediate. 'They're very into it; every morning they ask what we're going to play,' said Harper, who's worked at the centre for nine years and has a three-year-old daughter enrolled there. Marilyn Harper Marilyn Harper says the impact on children involved in active play was immediate. (CTV News) 'It's very special to bring this to them and to see the emotions when they're playing more, especially with all their friends.' She said the project is also allowing her to broaden her toolkit as an educator. 'Before, kids would mostly be left to play on their own, but now I have specific things to work on with them, like posture and balance,' said Harper. 'And I can already see they're more attentive and active.' The focus isn't just on movement for movement's sake. According to Côté, active play also teaches children how to manage emotions and navigate social situations by setting boundaries. 'They learn how to communicate their frustrations,' she said. 'Even if someone is their friend, they can say, 'This time, I need my space.' Those kinds of social skills are really useful for life.' At home, parents have noticed changes too. Geneviève Woods, a mother of four — two of whom attend the daycare — said her younger children have been more engaged and independent since the program started. 'It's such a challenge being able to fulfill their needs on a daily basis — like how they want me to play with them all the time, but meanwhile I have to prepare snacks and everything,' she said. 'Now, I see them playing games together, and it's not coming from me telling them how to do it. I can just meet them there, and my older kids also join in because it looks fun.' Woods said the program gave her new ideas and models to engage with her kids, and brought a boost in energy and happiness across the board. 'At the end of the day, I see them and their educators being happier,' she said. 'It brings something really positive and for parents, it's also helped us spend more quality time with them.' To track the impact, children in the study wear actimeters — devices that measure physical activity — for a week at the beginning and end of the program. Researchers will also observe school readiness and assess basic motor skills, with final results expected in two years. But for Côté, the mission is already clear: 'We want to give the kids a strong start.'
Toronto Star
14-06-2025
- Toronto Star
Amid upheaval abroad, universities urge Ottawa, Quebec to invest in attracting talent
MONTREAL - Four major Quebec universities are proposing initiatives to make the province a landing spot for high-level researchers. A joint statement released today highlights a number of moves, including co-ordinated steps at the national level to attract talent. The four universities — Université Laval, McGill University, Université de Montréal, and Université de Sherbrooke — hope to leverage political and social tensions affecting researchers around the world to lure them to Canadian schools. ARTICLE CONTINUES BELOW The group of universities, going by the name Polaris, say both Quebec and Ottawa have a role to play in making that happen. Vincent Poitout, vice-rector of research and innovation at Université de Montréal, says there is a window to transform a very unfortunate situation in science, particularly in the United States, into an opportunity for Canada. The universities note a recent survey published in Nature, a journal, that 75 per cent of researchers in the United States are considering leaving the country. This report by The Canadian Press was first published June 14, 2025.
